for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

109.18USD

Change

10.62(+10.78%)

Volume

25,850,691

Today's Range

98.65

 - 

109.29

52 Week Range

17.68

 - 

109.29

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
98.56
Open
99.03
Volume
25,850,691
3M AVG Volume
230.31
Today's High
109.29
Today's Low
98.65
52 Week High
109.29
52 Week Low
17.68
Shares Out (MIL)
395.71
Market Cap (MIL)
43,203.63
Forward P/E
-62.13
Dividend (Yield %)
--

Next Event

Moderna Inc at Piper Sandler Healthcare Conference (Virtual)

Latest Developments

更多

Moderna Announces The European Commission's Approval Of Advance Purchase Agreement For Initial 80 Million Doses Of COVID-19 Vaccine

Moderna’S Covid-19 Vaccine Candidate Meets Its Primary Efficacy Endpoint In The First Interim Analysis Of The Phase 3 Cove Study

Moderna Has Completed Case Accrual For First Planned Interim Analysis Of Its Vaccine Against Covid-19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David W. Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resource Officer

Key Stats

2.29 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020(E)

0.4K
EPS (USD)

2018

-4.950

2019

-1.550

2020(E)

-1.768
Price To Earnings (TTM)
--
Price To Sales (TTM)
175.12
Price To Book (MRQ)
15.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.94
LT Debt To Equity (MRQ)
3.94
Return on Investment (TTM)
-25.87
Return on Equity (TTM)
-19.15

Latest News

Latest News

EXPLAINER-When and how will COVID-19 vaccines become available?

Pfizer Inc with partner BioNTech SE and Moderna Inc have released trial data showing their COVID-19 vaccines to be about 95% effective at preventing the illness, while AstraZeneca Plc this week said its vaccine could be up to 90% effective.

UPDATE 4-EU secures 160 mln doses of Moderna's COVID-19 vaccine

The European Union has struck a deal for up to 160 million doses of U.S. firm Moderna's COVID-19 vaccine candidate, the head of the European Commission said on Tuesday, taking the EU's potential stock of COVID-19 shots to nearly 2 billion.

EU has deal with Moderna for supply of COVID-19 vaccine candidate- von der Leyen

The European Union has reached a deal with U.S. biotech firm Moderna for the supply of up to 160 million doses of its COVID-19 vaccine candidate, the president of the European Commission said on Tuesday.

EU drug regulator could rule on COVID-19 vaccines by year end - report

The European Medicines Agency (EMA) could produce a scientific opinion on COVID-19 vaccines seeking regulatory approval by the end of the year in a best case scenario, the regulator's new chief was quoted as saying on Tuesday.

UPDATE 3-Encouraging Oxford vaccine results keep Britain on track for spring roll-out

* PM Johnson: news demonstrates that pandemic will end (Adds UK PM Johnson)

Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virus

The experimental COVID-19 vaccine developed by AstraZeneca and Oxford University would have a higher efficacy rate if trials were only measuring whether the shot prevents hospitalisation and severe disease, Oxford's vaccine chief said on Monday.

Moderna to charge $25-$37 for COVID-19 vaccine - CEO tells paper

Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).

UPDATE 1-Pfizer, Moderna COVID-19 vaccines may be authorized for use within weeks -U.S. official

COVID-19 vaccines from Pfizer Inc and Moderna Inc could be ready for U.S. authorization and distribution within weeks, setting the stage for inoculation to begin as soon as this year, U.S. Health and Human Services Secretary Alex Azar said on Wednesday.

REFILE-Air France-KLM prepares COVID-19 vaccine airlift

Air France-KLM is among airlines gearing up for the challenge of transporting millions of doses of temperature-sensitive COVID-19 vaccines in the midst of a travel slump.

Pfizer, Moderna COVID-19 vaccines may be ready for U.S. authorization within weeks: U.S. official

Pfizer Inc's and Moderna Inc's COVID-19 vaccine candidates could be ready for U.S. authorization and distribution within weeks, setting the stage for widespread inoculation to begin as soon as this year, U.S. Health and Human Services Secretary Alex Azar said during a press...

Hong Kong shares end higher on vaccine hopes, stronger automakers

Hong Kong stocks ended higher for a third straight session on Wednesday, with the automotive sector leading gains, as investors continued to cheer news of COVID-19 vaccine breakthroughs.

ANALYSIS-Airlines scramble to prepare for ultra-cold COVID-19 vaccine distribution

Airlines are scrambling to prepare ultra-cold shipping and storage facilities to transport COVID-19 vaccines developed by Pfizer and Moderna, whose doses, which require deep freezing, are likely to be among the first to be distributed.

UPDATE 1-Moderna says UK deal will supply COVID-19 vaccine from March

Moderna Inc confirmed on Tuesday it had agreed to supply its COVID-19 vaccine candidate, mRNA-1273, to the United Kingdom starting from the beginning of March, as long as it succeeds in gaining local regulatory approval.

Moderna signs deal to supply COVID-19 vaccine to UK from March

Moderna Inc said on Tuesday it agreed to supply its COVID-19 vaccine candidate, mRNA-1273, to the United Kingdom beginning March, if it is approved by the local regulatory authorities.

Spain in negotiations to buy Moderna vaccine, Government spokeswoman says

The Spanish government is in a "very advanced phase" of negotiations to buy vaccines against COVID-19 being developed by pharmaceutical firm Moderna, spokeswoman Maria Jesus Montero said on Tuesday. (Reporting by Andrey Khalip and Inti Landauro Editing by Ingrid Melander)

UPDATE 5-We can stop COVID-19: Moderna vaccine success gives world more hope

* Experts encouraged by Moderna results (Updates shares, adds detail)

FOREX-Dollar steadies but concerns about coronavirus and Biden transition loom

* Currencies little moved on coronavirus vaccine progress * Growing unease about current rise in new infections * Traders in Asia focus on yuan's rise against greenback By Stanley White TOKYO, Nov 17 (Reuters) - The dollar steadied against most currencies on Tuesday as a...

Australia, NZ dollars resurgent on virus vaccine hopes

The Australian dollar climbed to a one-week high on Tuesday, holding above key chart resistance of 73 U.S. cents, while its New Zealand peer was perched at a 19-month top as investor sentiment was boosted by coronavirus vaccine hopes.

FOREX-Dollar nurses losses amid worries about second coronavirus wave, Biden transition

* Currencies little moved on coronavirus vaccine progress * Growing unease about current rise in new infections * Traders in Asia focus on yuan's rise against greenback By Stanley White TOKYO, Nov 17 (Reuters) - The dollar nursed losses on Tuesday as a return of coronavirus...

UPDATE 6-Oil settles higher boosted by latest COVID-19 vaccine progress

* OPEC+ October supply cut compliance seen at 96%, sources say

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up